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Histidine phosphorylation, the so-called hidden phosphoproteome, 
is a poorly characterized post-translational modification of 
proteins1,2. Here we describe a role of histidine phosphorylation 
in tumorigenesis. Proteomic analysis of 12 tumours from an 
mTOR-driven hepatocellular carcinoma mouse model revealed 
that NME1 and NME2, the only known mammalian histidine 
kinases, were upregulated. Conversely, expression of the putative 
histidine phosphatase LHPP was downregulated specifically in the 
tumours. We demonstrate that LHPP is indeed a protein histidine 
phosphatase. Consistent with these observations, global histidine 
phosphorylation was significantly upregulated in the liver tumours. 
Sustained, hepatic expression of LHPP in the hepatocellular 
carcinoma mouse model reduced tumour burden and prevented 
the loss of liver function. Finally, in patients with hepatocellular 
carcinoma, low expression of LHPP correlated with increased 
tumour severity and reduced overall survival. Thus, LHPP is a 
protein histidine phosphatase and tumour suppressor, suggesting 
that deregulated histidine phosphorylation is oncogenic.
Liver cancer is the second leading cause of cancer-related deaths 
globally. Hepatocellular carcinoma (HCC) represents approximately 
90% of primary liver cancer cases3. Recent studies indicate that almost 
50% of HCC cases display aberrant PI3K–AKT–mTOR signalling4, 
including loss of the tumour suppressors PTEN, TSC1, and TSC23 
(Fig. 1a). We generated an HCC mouse model by liver-specific dele-
tion of PTEN and TSC1, using the neonatally expressed albumin 
promoter as a cre driver (see Methods). We hereafter refer to this 
model as liver-specific double-knockout (L-dKO) mice. L-dKO mice 
invariably exhibited hepatomegaly and advanced liver tumours at 6 
and 20 weeks of age, respectively (Fig. 1b and Extended Data Fig. 1a). 
Histopathological analysis (Fig. 1b) and molecular classification based 
on mRNA expression of the liver cancer markers CD133 (also known 
as Prom1), CD90 (Thy1), Cd44 and Aldh1 (Aldh1a1) revealed that the 
L-dKO liver tumours indeed mimicked poorly differentiated human 
HCC (Extended Data Fig. 1b), consistent with other studies5,6.
We performed quantitative proteomic analysis on three tumours 
each from four 20-week-old, L-dKO mice (12 tumours in total; see 
Methods). Liver protein extracts from six cre-negative age- and sex-
matched littermates were pooled in equal amounts and used as a 
control (Extended Data Fig. 1c). We identified approximately 4,500 
proteins per tumour (Extended Data Fig. 1d). Of the 3,147 proteins 
that were detected in a minimum of 10 tumours, 433 proteins were 
upregulated and 262 proteins were downregulated compared to the 
control (Fig. 1c). We manually curated a list of known or putative phos-
phatases and kinases significantly deregulated in a minimum of ten 
tumours (Extended Data Fig. 1e). Particularly intriguing in this list 
were the upregulated histidine kinases NME1 and NME2 (also known 
as NDPKA and NDPKB, respectively) (Fig. 1d), and the downregulated 
putative histidine phosphatase LHPP (phospholysine phosphohistidine 
inorganic pyrophosphate phosphatase).
LHPP has been purified from bovine liver and shown to hydrolyse 
P–N bonds in synthetic substrates in vitro7–9, but is otherwise poorly 
characterized. LHPP is evolutionarily conserved from worm to human 
(overall 28% identity) (Extended Data Fig. 2a), but only weakly homo-
logous to the two defined mammalian histidine phosphatases PHPT1 
(8.1% identity) and PGAM5 (6.4% identity)10–12 (Extended Data Fig. 2b). 
We note that PHPT1 and PGAM5 levels were unchanged in tumours 
from L-dKO mice (Fig. 1d). NME1 and NME2 are homologous 
proteins (88% identical) that function as histidine kinases as either 
homo- or hetero-oligomers. NME1 and NME2 are the only mamma-
lian protein histidine kinases reported so far13–15. Immunoblot analysis 
confirmed that LHPP was downregulated and NME1 and NME2 were 
upregulated (Fig. 2a and Extended Data Fig. 3a) in L-dKO tumours, 
as initially observed by proteomic analysis. Immunoblot analysis of 
S6 protein phosphorylated at Ser240 and Ser244 (S6-pS240/244) and 
AKT phosphorylated at Ser473 (AKT-pS473) confirmed high mTORC1 
and mTORC2 activity, respectively, in L-dKO liver tissue and tumours 
(Fig. 2a, b). To determine whether the loss of LHPP expression coin-
cided with tumorigenesis, we examined whole liver tissue (6, 12 and 
16 weeks) and isolated tumours (20 weeks) from L-dKO mice at differ-
ent ages and hence at different stages of tumour development (Fig. 2b). 
Age-matched cre-negative littermates served as controls. LHPP expres-
sion was mildly reduced in the livers of L-dKO mice at 16 weeks, at 
which age macroscopic tumours were first visible. As observed previ-
ously, LHPP was strongly decreased in tumours of 20-week-old mice. 
As expected, mTOR signalling was high at all ages. Thus, the reduction 
in LHPP expression coincided with tumour development, but did not 
correlate with mTOR activity. Hepatic NME1 and NME2 expression 
decreased in control mice in an age-dependent manner, but remained 
high in L-dKO liver tissue and tumours. Thus, increased NME1 and 
NME2 expression in L-dKO mice correlated with increased mTOR 
activity rather than with tumour development (Fig. 2b), suggesting 
that mTOR may control NME1 and NME2 expression. To determine 
whether loss of LHPP expression was specific to tumours, we per-
formed immunoblot analysis on dissected tumour and non-tumour 
liver tissue from 20-week L-dKO mice. LHPP expression was reduced 
(or absent) in the tumour, compared to the non-tumour liver tissue 
(Extended Data Fig. 3b). Immunohistochemistry on liver from 20-week 
L-dKO mice confirmed that LHPP was strongly downregulated (unde-
tectable) in tumours compared to non-tumour tissue (Extended Data 
Fig. 3c). Like mTOR activity, NME1 and NME2 expression was simi-
larly upregulated in both tumour and non-tumour L-dKO liver tissue 
compared to control liver tissue (Extended Data Fig. 3b, c), again indi-
cating that the expression of NME1 and NME2 correlated with mTOR 
activity rather than tumorigenicity. These findings suggest that LHPP 
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inactivation, in a background of constitutively high NME1 and NME2 
activity in L-dKO liver, is a key event in tumorigenesis.
The above findings suggest that the expression of NME1 and NME2, 
but not LHPP, is controlled by mTOR. To investigate this further, we 
acutely treated (24 h) L-dKO mice with the mTORC1 inhibitor rapa-
mycin or the pan-mTOR inhibitor INK128. INK128 treatment reduced 
NME1 and NME2 expression in L-dKO tumours, but had no effect on 
LHPP (Extended Data Fig. 3d). Rapamycin had no effect on the level 
of NME1, NME2 or LHPP (data not shown). Thus, the expression of 
NME1 and NME2 seems to be mTORC2 dependent, whereas LHPP 
expression is mTOR independent.
The paired upregulation of NME1 and NME2 (histidine kinases) and 
downregulation of LHPP (putative histidine phosphatase) prompted us 
to investigate protein histidine phosphorylation in L-dKO tumours1,16. 
Phosphohistidine (pHis) exists in two isomers, 1-pHis and 3-pHis, 
depending on the position of the phospho-acceptor nitrogen in the 
histidine imidazole ring (N1 and N3 positions, respectively)2,17. Unlike 
the phosphoester (P–O) bond in other phosphoamino acids, the phos-
phoramidate (P–N) bond in phosphohistidine is heat- and acid-labile, 
thus making pHis difficult to detect in biological samples18. This difficulty 
has been largely circumvented by the recent development of monoclonal 
antibodies that specifically recognize 1-pHis or 3-pHis2. The new 
antibodies were used to assess histidine phosphorylation (1-pHis and 
3-pHis) in L-dKO tumours and control liver (Fig. 3a) (see Methods). 
The immunoblot signals of both 1-pHis and 3-pHis were high in 
tumours compared to control tissue (Fig. 3a, b). Heating sample-buffer- 
solubilized lysates at 95 °C for 10 min before SDS–PAGE caused 
dephosphorylation, indicating that the signals detected in the unheated 
samples are indeed histidine-phosphorylated proteins (Fig. 3a). 
As reported previously with cultured cells2, multiple 3-pHis- positive 
proteins but only one or a few 1-pHis proteins were detected in tumours 
and liver tissue. This could be due to the lower thermodynamic  stability 
of 1-pHis than of 3-pHis19,20, or the existence of fewer proteins phos-
phorylated at the N1 position. The major band observed with the 
1-pHis antibody is likely to be co-migrating NME1-pHis118 and 
NME2-pHis118 (Fig. 3a), because it displays an appropriate molecu-
lar mass (18 kDa) for NME1 and NME2 and was lost upon NME1 
and NME2 knockdown (data not shown). NME1 and NME2 normally 
autophosphorylate position N1 of His118, and then transfer this phos-
phate to histidine (N1 or N3) in target proteins (Extended Data Fig. 4a). 
Thus, consistent with increased levels of NME1-pHis118 and NME2-
pHis118 and decreased LHPP levels, histidine phosphorylation was 
significantly increased in L-dKO tumours.
To identify proteins in which histidine phosphorylation is increased 
in tumours, we used a combination of anti-1-pHis and anti-3-pHis 
monoclonal antibodies to immunoprecipitate pHis proteins from four 
L-dKO tumours and control tissue. Subsequent mass spectro metry 
identified 1,173 and 823 proteins from tumour and control liver  tissue 
lysates, respectively (Supplementary Tables 1 and 2). In total, 260 
 proteins were more abundant (at least twofold) in tumours compared 
to control tissue (Supplementary Table 3). Only 18 proteins were more 
abundant in control tissue (see below for more discussion).
We next investigated whether LHPP is indeed a protein phosphohis-
tidine phosphatase. First, we assayed LHPP phosphohistidine phos-
phatase activity in vitro (see Methods). Recombinant LHPP treatment 
reduced 3-pHis levels in an electrophoretically fractionated CB1 cell 
lysate transferred to a membrane (Extended Data Fig. 4b). CB1 is a cell 
line derived from L-dKO tumours (see Methods) and thus displays 
high levels of histidine phosphorylation. Second, we assessed LHPP 
phosphatase activity in vivo. Restoration of Lhpp expression in CB1 
cells, using an adenovirus delivery system, reduced 3-pHis 3.1-fold with 
negligible effect on 1-pHis, pSer/Thr or pTyr (Fig. 3c, d, Extended Data 
Fig. 4c). Similar results were obtained with regard to pHis (3.9-fold 
drop in 3-pHis, no effect on 1-pHis) after introducing mouse Lhpp into 
human SNU449 cells, a liver cancer cell line with low intrinsic LHPP 
levels (Extended Data Fig. 4d, e). Immunoblot analysis confirmed the 
expression of recombinant Lhpp in both cell lines (Fig. 3c and Extended 
Data Fig. 4d). Collectively, these results indicate that LHPP is a histidine 
phosphatase broadly acting on N3-phosphorylated proteins. We note 
that PGAM5 was previously demonstrated12 to be a 1-pHis phosphatase 
acting specifically on NME2-pHis118.
To identify potential LHPP targets, we immunoprecipitated 
N3-phosphorylated proteins from CB1 cells lacking and re- expressing 
LHPP. Mass spectrometry revealed nine proteins that were more abun-
dant (at least 1.7-fold) in CB1 cells that lack LHPP (Supplementary 
Table 4). These included ACLY (ATP citrate lyase), known to be 
N3-phosphorylated at His760 (see below).
We next examined further the role of the phosphatase LHPP in pro-
liferation and tumorigenesis. Increased expression of LHPP in CB1 
and SNU449 cells significantly impaired cell proliferation and, in CB1 
cells, reduced hepatosphere formation (Extended Data Fig. 4f, g). 
Conversely, knocking down the already low level of LHPP expression in 
SNU449 cells enhanced cell proliferation (Extended Data Fig. 5a). Next, 
we investigated the effect of LHPP expression on tumour formation 
in L-dKO mice. Hepatocyte-specific, adeno-associated virus (AAV) 
expressing either red fluorescent protein (RFP) (AAV/DJ-ALBp-RFP, 
hereafter referred to as AAV-control) or RFP and murine LHPP (AAV/
DJ-ALBp-RFP-2A-mLhpp, hereafter referred to as AAV-LHPP) was 
injected into the tail vein of 8-week-old L-dKO and littermate con-
trol mice (Fig. 3e). Tumour burden was assessed at 20 weeks of age. 
Hepatic overexpression of LHPP in AAV-LHPP-infected L-dKO mice 
(20 weeks) was confirmed by immunoblotting (Extended Data Fig. 5b). 
Macroscopic and histological examination of livers revealed few and 
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Figure 1 | Proteomics on L-dKO tumours. a, Diagram of mTOR 
signalling showing TSC and PTEN tumour suppressors. b, Top, 
representative images of whole livers from 20-week-old L-dKO (tumours 
indicated with arrowheads) and control mice. Bottom, representative 
photomicrographs of haematoxylin and eosin (H&E)-stained liver 
from control mice, tumour (T) and adjacent non-tumour (NT) tissue 
from L-dKO mice (20 weeks). Similar results were obtained in tumours 
from nine mice. c, Number of tumour proteins detected and quantified by 
mass spectrometry. A total of 7,753 proteins were quantified in all tumours 
(n = 12). 3,147 proteins were quantified in a minimum of 10 tumours, 
of which 433 proteins were upregulated (red), 262 were downregulated 
(blue), and 2,452 were unchanged (yellow). ANOVA-based two-sample 
t-test with a false discovery rate (FDR) of 2% was used to determine 
regulation. d, Mass spectrometry-determined fold change in independent 
L-dKO tumours (n = 12 for NME1, NME2, LHPP and PHPT1; n = 9 for 
PGAM5) compared to control livers (n = 6);  
data are mean ± s.d. PHPT1 and PGAM5 are two defined mammalian 
histidine phosphatases.
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small (micronodular) tumours in AAV-LHPP-infected L-dKO mice 
(Fig. 3e–g). The few ‘escaper’ tumours that arose in AAV-LHPP-
infected L-dKO mice displayed reduced LHPP expression, again 
suggesting that LHPP downregulation is essential for tumorigenesis. 
AAV-control-infected L-dKO livers exhibited severe HCC with multiple 
large neoplastic (macronodular) tumours. Serum levels of alanine 
amino transferase (ALT), aspartate amino transferase (AST) and lactate 
dehydrogenase (LDH), well characterized indicators of liver damage, 
were also reduced in AAV-LHPP-infected L-dKO mice compared to 
AAV-control-infected mice (Extended Data Fig. 5c). No detrimental 
effect was observed in control mice injected with either AAV-control 
or AAV-LHPP (Extended Data Fig. 5c). Thus, the expression of LHPP 
 prevents tumour formation and maintains liver function in L-dKO 
mice, suggesting that the protein histidine phosphatase LHPP is a 
tumour suppressor.
We next examined NME1, NME2 and LHPP expression in human 
liver tumours, from patients with HCC. Resected HCC tissue and 
adjacent non-tumour tissue were assessed for LHPP, NME1 and 
NME2 levels by immunoblot analysis. LHPP was low in the tumour 
(HCC) compared to non-tumour tissue in several patients (Fig. 4a), 
as observed in L-dKO mice. NME1 and NME2 expression was high 
in the tumours. We note that human NME1 and NME2, unlike their 
mouse counterparts, do not co-migrate (Fig. 4a). In agreement with the 
immunoblot analysis, immunohistochemistry also showed that LHPP 
expression was low and NME1 and NME2 expression was high in HCC 
compared to adjacent non-tumour tissue from two additional patients 
(Fig. 4b). Furthermore, using a tissue microarray assay, we evaluated 
LHPP expression in tumour and matched non-tumour liver samples 
from 20 patients with HCC. Tumour sections that had greater than 70% 
tumour cells and non-tumour sections that contained greater than 70% 
normal cells were chosen for the array (see Methods). LHPP expres-
sion was significantly downregulated in HCC compared to matched 
non-tumour tissue (Extended Data Fig. 6a–c). Similarly, on the basis 
of a published mRNA expression dataset from 37 patients with HCC21, 
LHPP mRNA levels (but not PHPT1 or PGAM5 mRNA levels) were 
significantly reduced in tumour tissue compared to matched non- 
tumour tissue (Extended Data Fig. 6d). We note that, in L-dKO mice, 
reduced LHPP protein expression also correlated with reduced Lhpp 
mRNA levels (Extended Data Fig. 1f). Finally, consistent with increased 
levels of NME1 and NME2 and decreased levels of LHPP (Fig. 4c), we 
observed significantly higher 1-pHis and 3-pHis signals in human HCC 
compared to matched non-tumour tissue (Fig. 4c, d). Collectively, the 
above findings suggest that histidine phosphorylation is upregulated 
in both mouse and human tumours.
We next investigated clinical correlates of LHPP expression. HCC 
is scored based on Edmondson grades I to IV in which grade IV is 
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Figure 2 | Loss of LHPP expression is confined to L-dKO tumours. 
a, Immunoblot analysis indicates reduced LHPP and increased NME1 
and NME2 expression in tumours compared to age-matched littermate 
control (liver samples from control mice (n = 4) and two tumour samples 
each from four 20-week-old L-dKO mice (n = 8)). For full scans, see 
Supplementary Fig. 1. b, Immunoblot analysis indicates reduced LHPP 
expression (16 and 20 weeks (w)) and increased NME1 and NME2 
expression (12, 16 and 20 weeks) in L-dKO liver (6, 12 and 16 weeks) and 
tumours (20 weeks) compared to age-matched control mice (6, 12 and 
16 weeks, n = 4, liver tissues from two mice are pooled per lane). For full 
scans, see Supplementary Fig. 2.
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Figure 3 | LHPP is a protein histidine phosphatase and a tumour 
suppressor. a, b, Immunoblot analysis (a) and quantification (b), shows 
increased 3-pHis and 1-pHis signals in L-dKO tumours (20 weeks) 
compared to control (ctrl) littermates. Similar results were observed in 
tumours from L-dKO mice (n = 4). Tissue lysates in 2× sample buffer 
(pH 8.8) heated at 95 °C for 10 min were dephosphorylated and served 
as a control. For full scans, see Supplementary Fig. 5. In the 3-pHis blot, 
the area enclosed in the dashed line was used for quantification (n = 4). 
Adjusted * P = 0.0460, * * P = 0.0051, two-sided, Holm–Sidak’s  
multiple comparisons test. Data are mean ± s.d. M, molecular mass.  
c, Immunoblotting shows a reduction in 3-pHis levels in CB1 cells infected 
with adenovirus (adeno) containing LHPP, compared to cells infected with 
a control adenovirus. Similar results were observed in three biological 
experiments. For full scans, see Supplementary Fig. 7. d, Quantification of 
immunoblots indicate that 3-pHis signals are significantly reduced upon 
LHPP re-expression compared to control-infected cells (n = 3 biological 
repeats). * * * * P < 0.0001, two-sided ratio paired t-test. NS, not significant. 
Data are mean ± s.d. e, Top, experimental timeline. AAV-control or AAV-
LHPP was injected into the tail vein of 8-week-old L-dKO and littermate 
control mice. Bottom, representative images of whole livers showing 
reduction in L-dKO liver tumour burden after infection with AAV-LHPP 
compared to infection with AAV-control (arrowheads indicate tumours). 
Similar results were observed in five different L-dKO mice infected with 
AAV-LHPP. f, Photographs of tumours isolated from L-dKO mice infected 
with AAV-LHPP and AAV-control. g, Quantification of tumours in L-dKO 
mice showing a significant reduction in tumour burden after infection 
with AAV-LHPP (n = 5 mice), compared to AAV-control (n = 6 mice).  
* * * * P < 0.0001, two-sided unpaired t-test. Data are mean ± s.d.
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the most severe or aggressive. Examination of a previously published 
mRNA dataset21 revealed that low LHPP expression is associated with 
more severe tumours (Edmondson grades III/IV versus I/II) (Extended 
Data Fig. 6e). These results, combined with our earlier observa-
tion that LHPP expression in L-dKO mice reduced tumorigenicity 
(Fig. 3e–g), suggest that low LHPP expression could correlate with 
reduced patient survival. We referred to The Cancer Genome Atlas 
(TCGA) to determine whether there is a correlation between LHPP 
expression and overall survival or disease-free survival (see Methods). 
LHPP downregulation was associated with faster disease progression 
and worse overall survival in 319 and 370 patients with HCC, respec-
tively (Fig. 4e, f). Median disease-free survival and overall survival 
of patients with HCC decreased from 25 to 12 months and from 61 
to 38 months, respectively, after the loss of LHPP expression. Thus, 
decreased LHPP expression in human HCC is associated with increased 
histidine phosphorylation and reduced survival.
We identified 49 LHPP mutations in datasets from TCGA and the 
International Cancer Genome Consortium (ICGC). Twelve (24.5%) of 
the mutations, found in oesophagus (2), head and neck (2), stomach 
(2), bladder (1), breast (1), skin (1), liver (1), lung (1), and pancreas 
(1), are predicted to be inactivating mutations (Extended Data Fig. 6f), 
that is, nonsense, frameshift or splice site mutations (Supplementary 
Table 5). The > 20% prevalence of inactivating mutations suggests that 
LHPP is a tumour suppressor gene22. This suggestion is strengthened 
by two genome-wide association studies (GWAS) indicating that the 
LHPP locus is associated with oral cancer, pharyngeal cancer and 
acute lymphoblastic leukaemia23,24. Whole-genome sequencing pre-
viously identified the LHPP locus as a risk factor for major depressive 
disorder25,26. These observations suggest that loss of LHPP and thus 
increased histidine phosphorylation is oncogenic and possibly also 
involved in other disorders. Importantly, the results collectively suggest 
that LHPP is a histidine phosphatase and tumour suppressor.
How might histidine phosphorylation be related to cancer? The 
 histidine-phosphorylated proteins we detected preferentially in 
tumours include the crucial DNA replication factors MCM3, MCM6 
and MCM7, the p53 inhibitor AROS, the cytidine deaminase ABEC3 
that converts cytosine to uracil and may induce mutations, the receptor- 
mediated endocytosis and NOTCH signalling protein AAK1, the 
mTORC1 effector RSK227, and CHTOP. The potential LHPP targets 
we detected that might be important for tumorigenesis include the 
essential fatty acid biosynthetic enzyme ACLY6, the proto-oncoprotein 
and RNA polymerase-associated protein LEO128, a variant histone 
H2A commonly expressed in HCC29, and the inflammation-related 
and HCC-promoting HMGB1 protein30 (Supplementary Table 4).
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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Figure 4 | Loss of LHPP expression in human HCC correlates with 
reduced patient survival. a, b, Immunoblot (n = 3 patients) (a) and 
immunohistochemistry (b) (n = 2 patients) analyses showing reduced 
LHPP and increased NME1 and NME2 expression in liver tissue from 
patients with HCC compared to adjacent non-tumour liver tissue in a total 
of n = 7 HCC patients (n = 2 other patients in panel c). For full scans, see 
Supplementary Fig. 12. c, Immunoblot analysis showing increased 3-pHis 
and 1-pHis signals in human HCC compared to adjacent non-tumour 
tissue. Similar results were observed in tumours from two additional HCC 
patients (total n = 4 patients). For full scans, see Supplementary Fig. 13. 
Tissue lysates in 2× sample buffer (pH 8.8) heated at 95 °C for 10 min to 
dephosphorylate pHis served as control. The monoclonal antibodies  
used to detect 3-pHis and 1-pHis are SC44-1 and SC1-1, respectively.  
d, Quantification of immunoblot (from c and two other western blots, 
n = 4 in total) indicates that 3-pHis and 1-pHis signals are significantly 
higher in human HCC compared to adjacent non-tumoral tissue (band 
intensities in each lane are normalized to the intensity of corresponding 
calnexin protein levels after subtracting the intensities from corresponding 
heated lane). The y axis represents band intensities. * P = 0.0368,  
* * P = 0.0064, two-sided ratio paired t-test. Data are mean ± s.d.  
e, f, Kaplan–Meier curves, log-rank test, showing the correlation  
between LHPP expression and clinical outcome, as analysed for disease-
free survival (e) and overall survival (f).
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MethOdS
Animals. Liver-specific Tsc1 and Pten double-knockout mice were obtained by 
crossing Tsc1lox/lox mice (exons 17 and 18)31 with Ptenlox/lox mice (exons 4 and 
5)32 to transgenic mice expressing Cre recombinase under the control of the 
hepatocyte-specific albumin promoter (Alb-CreTg/0)33, to generate liver-specific 
double-knockout (Tsc1lox/loxPtenlox/lox Alb-CreTg/0, in short L-dKO) mice. Age- 
and sex-matched littermate Tsc1lox/loxPtenlox/lox mice without the cre genes were 
used as controls in all animal experiments. No other randomization protocol or 
blinding was applied beyond this criterion. The mice produced were on mixed 
genetic background (C57BL/6J, 129/SvJae, BALB/cJ). Mice were housed under 
temperature and humidity-controlled conditions, in a 12-h light/dark cycle with 
lights switched on between 06:00 to 18:00. All experiments were conducted on male 
mice (age between 6 and 20 weeks). In all experiments, mice were fasted overnight 
before euthanasia by CO2 inhalation. All relevant ethical regulations were followed 
in this study. The tumour harvest time limit was set at 20 weeks. In addition, the 
clinical conditions of mice were monitored according to the score sheet as stipu-
lated by the Institutional Animal Care and Use Committee (IACUC), Kantonales 
Veterinaeramt of Kanton Basel-Stadt. None of the guidelines was exceeded in any 
experiment performed. For all animal experiments, respecting the animal ethical 
rules, a minimum number of animals required to get a statistically meaningful 
result were used. All animal experiments were performed in accordance with the 
federal ethical guidelines and were approved by the Kantonales Veterinaeramt of 
Kanton Basel-Stadt.
Mass spectrometry. Sample preparation for proteome analysis of tumours. Tumours 
from 20-week-old L-dKO mice and whole liver from littermate control mice were 
carefully dissected under magnifying lens and snap-frozen in liquid nitrogen. 
Frozen tissue was pulverized in a metal plate cooled on dry ice and was trans-
ferred into a cooled microcentrifuge tube. The powdered tissue was resuspended 
in 8 M urea (Applichem, A1086) (containing 50 mM Tris-HCl (pH 8.0), 150 mM 
NaCl, 1 mM PMSF, 1× Complete Mini Protease Inhibitors (Roche),1× PhosSTOP 
(Roche)) and homogenized using a Polytron (PT 10-35 GT) at 500g for 2 min. 
The sample was placed on ice during this process. Lysates were then subjected to 
rotation at 4 °C with regular vortexing. Lysates were then centrifuged at 10,000g 
for 10 min at 4 °C to remove cell debris. Protein concentration in the supernatant 
was determined using Bradford assay. Equal amounts (5 mg each) of ‘pooled con-
trol’ and tumour tissue were reduced with 2.5 mM dithiothreitol (DTT) (Sigma) 
for 45 min at 56 °C, cooled for 5–10 min at room temperature and alkylated with 
7.5 mM iodoacetamide (IAA) (Sigma) for 45 min at room temperature (reaction 
protected from light). The urea concentration was reduced to 4 M by diluting 
with 25 mM Tris-HCl, pH 8.0. Proteins were treated with endoproteinase LysC 
(1:100 (w/w), Wako) at 37 °C for 2 h. The urea concentration of the LysC digest was 
reduced to 1 M. Later, trypsin (Worthington) digestion (1:100; w/w) was performed 
for 2 h at 37 °C, followed by a second round of trypsin digestion (1:100; w/w) over-
night at 37 °C. Digestion was stopped by adding 0.4% trifluoroacetic acid (TFA) 
(Applied Biosystems) (v/v) that lowered the pH of the solution to below pH 2.0. 
Later, the digest was centrifuged at 10,000g for 10 min at room temperature and the 
supernatant was desalted on a C18 reverse-phase SepPak-200mg column (Waters). 
First, the cartridge was primed with 2 ml 100% acetonitrile (ACN) (Biosolve), 
followed by 4 ml of 50% acetonitrile containing 0.5% acetic acid (Merck) and 
equilibrated with 4 ml 0.1% TFA. Peptides were loaded twice in 0.4% TFA and 
the cartridge was washed with 10 ml of 0.1% TFA. Later, the cartridge was washed 
with 0.5% acetic acid and the peptides were eluted with 4 ml of 80% ACN, 0.5% 
acetic acid. The peptides were dried in a SpeedVac and subjected to strong cation 
exchange chromatography (SCX). SCX fractionation was performed according 
to34 with a few modifications detailed below. Storage buffer was removed from a 
HiTrap SP cartridge (GE Healthcare, 17115101) and washed twice with 2 ml of SCX 
buffer A (5 mM KH2PO4 (pH 2.65), 30% can). Later, the cartridge was equilibrated 
twice with 2 ml of SCX buffer B (5 mM KH2PO4 (pH 2.65), 30% ACN containing 
500 mM KCl), and the cartridge was re-equilibrated with 2 ml of SCX buffer A. The 
peptides were resuspended in 1 ml of SCX buffer A, centrifuged at 10,000g for 2 min 
to remove any unwanted debris. The peptides were then loaded with a syringe 
onto the HiTrap SP cartridge. The flow-through was then collected. The bound 
peptides were then desorbed in a stepwise manner: with 1 ml each of SCX buffer 
A containing 50 mM, 100 mM, 150 mM, 250 mM and 350 mM KCl. Each fraction 
was collected and the peptide concentration was estimated at 280 nm. The fractions 
were dried in a SpeedVac and peptides were then desalted on Microspin cartridges 
(Vydac). 10 μ g of each fraction was removed for liquid chromatography–tandem 
mass spectrometry (LC–MS/MS proteome analysis).
LC–MS/MS analysis. Dried peptides were dissolved in 20 μ l of 0.1% acetic acid, 
0.005% TFA. The peptides were analysed by capillary LC–MS/MS using a home-
made separating column (0.075 mm × 18 cm) packed with Reprosil C18 reverse-
phase material (2.4 μ m particle size). The column was connected on line to an 
Orbitrap FT hybrid instrument (Thermo Scientific). Solvent A (0.1% acetic acid 
in water, 0.005% TFA) and solvent B (0.1% acetic acid, 0.005% TFA and 80% ace-
tonitrile in water) were used for peptide separation. 2 μ l of peptide digest were 
injected with a Proxeon Easy-LC capillary pump (Thermo Scientific) set to 
0.3 μ l min−1. A gradient from 0 to 40% solvent B in solvent A in 190 min was 
delivered with the nano pump at a flow rate of 300 nl min−1. The percentage of 
solvent B was increased to 75% in 10 min at the end of the gradient. Later, the 
eluting peptides were ionized at 2.5 kV and mass spectrometer was operated in 
data-dependent mode. The precursor scan was done in the Orbitrap set to a 60,000 
resolution, while the fragment ions were mass analysed in the LTQ instrument. 
A top twenty method was used for fragmentation.
Protein identification. The LC–MS/MS data were searched with Proteome 
Discoverer 1.4 (Thermo Scientific) set to Mascot and Sequest HT search engines 
with 10 ppm precursor ion tolerance. The fragment ions were set to 0.6 Da 
 tolerance. Medium confidence (5% FDR) was used for peptide search. Swiss-Prot 
KB database set to M. musculus was used for Mascot. For Sequest HT, an inhouse 
databank was constructed by extracting M. musculus entries from UniProtKB.
Quantification. The raw files from the LC–MS/MS were first passed through 
Progenesis QI software (Nonlinear Dynamics, Waters) and the matched SCX 
fractions between ‘pooled control’ and tumours were aligned. A minimum of 75% 
alignment was set for analysis. During alignment, the search identifications from 
Proteome Discoverer (version 1.4) were imported into Progenesis for matching 
the aligned features with the identified peptides.
Statistical analysis. R-based Perseus program, version 1.4.0.2, was used for statis-
tical data analysis. An ANOVA-based two-sample t-test was performed, adjusting 
S0 to 1, the number of randomizations to 250 (default), and the FDR to 5% for the 
proteome35,36. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001.
p-His antibody immunoprecipitation of proteins for mass spectrometry. Tissue 
and cell lysis for pHis immunoprecipitation. Tumours from 20-week-old L-dKO 
mice and whole liver from littermate control mice were carefully dissected under 
magnifying lens and snap-frozen in liquid nitrogen. Frozen tissue was pulverized 
in a metal plate cooled on dry ice and was transferred into a cooled microcentrifuge 
tube. The powdered tissue was resuspended in 25 mM Tris-HCl (pH 8.5); 100 mM 
NaCl, pH: 8.5; 1 mM PMSF, 1× Complete Mini Protease Inhibitors (Roche), 
1× PhosSTOP (Roche) and homogenized using a Polytron (PT 10-35 GT) at 500g 
for 2 min. Precautions were taken to preserve pHis (pH 8.5 and constant 4 °C) and 
reagents (such as detergents) that can interfere with mass spectrometry. The sample 
was placed on ice during this process. Lysates were then incubated at 4 °C on an 
end-over-end rotator for 2 h with regular vortexing. Lysates were then centrifuged 
at 10,000g for 10 min at 4 °C to remove cell debris. Protein concentration in the 
supernatant was determined using BCA assay. Tissue lysate from four different 
littermate control animals was pooled to obtain a pooled control. For immuno-
precipitation of pHis proteins from CB1 cells with and without LHPP, 2 mg for 
each condition was used.
Bead preparation and preclearing of the lysate. One millilitre of protein A Sepharose 
beads (Thermo, 101042) was mixed with 1 ml of lysis buffer (25 mM Tris-HCl 
(pH 8.5); 100 mM NaCl, pH: 8.5; 1 mM PMSF, 1× Complete Mini Protease 
Inhibitors (Roche), 1× PhosSTOP (Roche)) and washed twice (by spinning at 
2,000g, 4 min, 4 °C) and resuspended in 2 ml of lysis buffer. For pre-clearing, the 
protein lysate (10 mg for tissues, 2 mg for cells) was incubated with 200 μ l of pre-
pared beads and incubated at 4 °C on an end-over-end rotator for 2 h. Later, the 
lysate was spun (2,000g, 4 min, 4 °C) and the precleared lysate (supernatant) was 
divided into two different tubes (5 mg each for tissues, 1 mg each for cells).
Antibody-lysate incubation. For tissue lysates, both 1-pHis and 3-pHis (clones 
SC1-1 and SC44-1) antibodies were used. For cell lysates, only 3-pHis antibody 
was used. Lysates were incubated with pHis antibody (30 μ g of 3-pHis plus 10 μ g 
of 1-pHis for tissue lysate; 30 μ g of 3-pHis for cell lysate) or IgG antibody (40 μ g 
for tissue lysate and 30 μ g for cell lysate). Lysates were incubated at 4 °C on an 
end-over-end rotator for 2 h. Later, 200 μ l of beads in lysis buffer were added and 
incubation continued at 4 °C on an end-over-end rotator for 12 h.
Washing the beads and elution of the proteins. The column was washed four times 
with 2 ml of lysis buffer (pre-cooled) at 4 °C. After the third wash, the fourth 
wash was performed in a new microcentrifuge tube to avoid any contamination 
from proteins attached to the wall of the microcentrifuge tube. Proteins were 
eluted in two fractions (E1 and E2) with 2× 600 μ l 100 mM triethylamine (TEA), 
pH 11. The fractions were dried in a SpeedVac and resuspended in 50 mM 
Tris-HCl (pH 7.5).
Sample preparation. The eluate in 50 mM Tris-HCl was treated with endoproteinase 
LysC (1:100 (w/w), Wako) at 37 °C for 2 h. Later, trypsin (Sigma) digestion (1:100; 
w/w) was performed for 2 h at 37 °C (pH 8.0), followed by a second round of 
trypsin digestion (1:100; w/w) overnight at 37 °C. Digestion was stopped by adding 
0.4% TFA (Applied Biosystems) (v/v) that lowered the pH of the solution to below 
pH 2.0. Later, the digest was centrifuged at 10,000g for 10 min at room temperature 
and the supernatant was desalted on Microspin cartridges (Vydac).
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First, the cartridge was activated with 100 μ l methanol, followed by 100 μ l 80% 
ACN, 0.5% acetic acid and the column was equilibrated with 2 × 100 μ l 0.1% TFA, 
1% ACN. Peptides were loaded twice in 0.4% TFA and the cartridge was washed 
five times with 100 μ l 0.1% TFA, 1% ACN. Later, the peptides were eluted with 
2 × 100 μ l 80% ACN, 0.5% acetic acid. The peptides were dried in a SpeedVac 
and subjected to LC–MS/MS proteome analysis. For further details, please see the 
‘LC–MS/MS analysis’ section above.
Protein identification. The LC–MS/MS data were searched with MaxQuant37, 
version 1.5.3.8 and searched against the mouse Swiss-Prot database 2017-05-09. 
A mass tolerance of 20 p.p.m. was allowed for the first search, and a mass 
tolerance of 10 p.p.m. was allowed for the main search. Two missed cleavages 
were allowed. Peptide FDR, protein FDR, and site decoy fraction were set to 
2%. For protein quantification, a ratio count of 1 was applied. The fragment 
ions were set to 0.6 Da tolerance. Medium confidence (5% FDR) was used for 
peptide search.
Quantification. The protein groups datasets were exported into a FileMaker 
Pro-12 databank.
Identification of proteins with histidine phosphorylation in tumours. Samples 
were run in triplicates. Label-free quantification (LFQ) intensities were obtained 
for each protein from MaxQuant. A mean of LFQ intensities was calculated and 
used for all further calculations. Proteins without any ratio owing to no detection 
in either of the samples were also included in the analysis. Mass spectrometry 
analysis identified 3,265 proteins in the tumour immunoprecipitate from a total of 
4 different L-dKO tumours. A total of 1,508 proteins were at least twofold-enriched 
in the pHis immunoprecipitate compared to the control IgG immunoprecipitate 
in more than 1 tumour. Out of these, 1,173 proteins were detected and enriched 
(minimum twofold) in 2 out of 2 tumours (100%), or 3 out of 3 tumours (100%), 
or 3 out of 4 tumours (75%, 100%) (Supplementary Table 2).
Identification of proteins with histidine phosphorylation in control tissue. Mass 
spectrometry analysis identified 3,011 proteins in the control tissue immunopre-
cipitate from a total of 4 different control animals. A total of 1,141 proteins were 
at least twofold-enriched in the pHis immunoprecipitate compared to the control 
IgG immunoprecipitate in more than 1 tumour. Out of these, 823 proteins were 
detected and enriched (minimum twofold) in 2 out of 2 control tissues (100%), 
or 3 out of 3 control tissues (100%), or 3 out of 4 control tissues (75%, 100%) 
(Supplementary Table 1).
Identification of proteins with increased histidine phosphorylation in 
tumours. Out of the proteins detected in tumour (1,173) and control (823) tis-
sue, 236 proteins were detected and enriched (minimum twofold) in 2 out of 2 
experiments (100%), or 3 out of 3 experiments (100%), or 3 out of 4 experiments 
(75%, 100%) (Supplementary Table 3). A total of 24 proteins that are exclusively 
detected in tumour tissue and hence had no ratio are indicated in the list shown 
in Supplementary Table 3.
Identification of proteins with decreased histidine phosphorylation in CB1 cells 
upon LHPP re-expression. Mass spectrometry analysis identified 295 proteins in 
the CB1 immunoprecipitate from a total of 5 different experiments. Nine proteins 
were at least 1.7-fold enriched in the CB1 cells lacking LHPP compared to the 
control IgG immunoprecipitate and LHPP re-expressing cells in minimum 50% 
of the experiments (Supplementary Table 4).
Antibodies. PTEN (CST, 9188), TSC1 (Bethyl, A300-316A), phospho-S6 (CST, 
4856), total S6 (CST, 2217), pAKT S473 (CST, 9271), total AKT (CST, 9272), 
Calnexin (Enzo, ADI-SPA-860), NME1 (CST, 3345), NME2 (Abcam, ab60602), 
and LHPP (Novus, NBP1-83273) were obtained commercially. Phospho-histidine 
monoclonal antibodies against N1 and N3 positions were as described previously2. 
The monoclonal antibodies used to detect 3-pHis and 1-pHis were SC44-1 and 
SC1-1, respectively. Horseradish peroxidase (HRP)-coupled anti-mouse (115-035-
774) and anti-rabbit (211-032-171) secondary antibodies were purchased from 
Jackson laboratories.
Immunoblot analysis. For regular immunoblot analysis, the liver tissue was 
homogenized in T-PER (ThermoFisher scientific, 78510) supplemented with 1 mM 
PMSF, 1× Complete Mini Protease Inhibitors (Roche), 1× PhosSTOP (Roche) 
using a Polytron (PT 10-35 GT) at 500g for 2 min. Equal amounts of homogenate 
were SDS–PAGE fractionated and transferred onto a nitrocellulose membrane 
that was incubated, after blocking (5% BSA in TBST), with appropriate antibodies. 
For phosphohistidine analysis, tissues (equal wet weights) and equal number of 
cells were lysed directly in 2× pHis sample buffer (5× pHis sample buffer: 250 mM 
Tris-HCl pH 8.8, 0.02% bromophenol blue, 50% glycerol, 50 mM EDTA, 500 mM 
DTT and 10% SDS), incubated on ice and sonicated (15 s × 3 times, Hielscher 
VialTweeter) to disrupt cells and shear DNA. Lysates were clarified by centrifu-
gation (10,000g for 15 min at 4 °C). Fresh lysates were resolved immediately using 
polyacrylamide gels at 4 °C with a modified stacking gel, pH 8.8 and 10% resolv-
ing gel, pH 8.8. All electrophoresis and protein transfer was strictly carried out 
at 4 °C. In addition, the running and transfer buffers were precooled before use. 
The nitrocellulose membranes were blocked in casein blocking buffer (0.1% casein, 
10% PBS, pH 8.8). Primary antibodies were resuspended in casein blocking buffer 
with 0.1% Tween-20, incubated overnight at 4°C. The monoclonal antibodies used 
to detect 3-pHis and 1-pHis were SC44-1 and SC1-1, respectively at a dilution of 
0.5 μ g ml−1. The membranes were washed three times (15 min per wash at 4 °C) 
with TBST (modification, pH 8.8) and incubated with anti-rabbit HRP conjugated 
secondary antibody (1:10,000) at 4 °C. Lysates in sample buffer (pH 8.8) heated 
at 95 °C for 10 min to dephosphorylate pHis served as a control. The bands in the 
heated lane are either heat-resistant pHis bands or a non-specific signal. For quan-
tification of the pHis immunoblots, band intensities in each lane are normalized to 
intensity of corresponding calnexin protein levels after subtracting the intensities 
from corresponding heated lane; the y-axis represents band intensities.
Immunoblot analysis on Lhpp adenovirus-infected cells. A 50–60% conflu-
ent dish was first infected, 24 h after infection, the cells (CB1 or SNU449) were 
trypsinized and 2 × 105 cells were seeded into a 6-well adherent tissue culture dish 
and 24 h later lysed in pHis compatible buffer (2× pHis sample buffer, for buffer 
composition, see the ‘Immunoblot analysis’ section above).
Crystal violet staining. On Lhpp-adenovirus infected cells. Twelve hours after 
infection, CB1 (2 × 104 per well) and SNU449 (4 × 104 per well) cells were 
seeded into a 6-well plate and stained with crystal violet (2% crystal violet in 
20%  methanol) on day 7 (n = 4). The plate was left to dry at room temperature. 
Absorbance was measured at 560 nm on a Tecan Infinite M1000 machine. The 
software used to control was Tecan i-control, version 1.11.1.0, according to the 
manufacturer’s instructions. Reference (or blank) was set with an empty 6-well 
plate. Multiple reads were read per well (15 × 15 reads) and a border of 3,000 μ m 
was left in each well. Number of flashes was set to 25 with 10 ms of settle time.
On LHPP-siRNA-transfected cells. LHPP siRNA (human LHPP ON-TARGET 
plus set of 4, pooled, catalogue number LQ-018950-02-0005; siRNA 1 
CAACCCAAACUGUGUGGUA, siRNA 2 CAUGAAGGCGCUUGAGUAU, 
siRNA 3 GCAGCACGCCGACAAGUGA, siRNA 4 CUGAAGCGUUCCCG 
GCUGA) and negative control siRNA (ON-TARGET plus non-targeting pool) 
were purchased from Dharmacon. SNU449 cells were transfected in the presence 
of the transfection reagent jetPRIME (PolyPlus transfection) as per the manufac-
turer’s instructions. Cells were then re-suspended in complete DMEM plus 10% 
FBS medium. Then 36 h after transfection, SNU449 cells were re-transfected with 
LHPP siRNA and were seeded in a 6-well plate (4 × 104 per well). The cells were 
stained with crystal violet (2% crystal violet in 20% methanol) on day 3.
Cell culture. CB1 cells were established from 20-week-old L-dKO tumours. 
Multiple L-dKO tumours were chopped finely into small pieces and washed in 
warm 20 ml PBS. The processed tumour tissues were seeded in a 6-well tissue 
culture dish in DMEM with 10% FBS. Six different clones, CB1–CB6 were selected 
by limited trypsinization and amplified in DMEM with 10% FBS. Clone CB1 
(transformed in vivo) was used for all future assays. SNU449 cells were obtained 
from ATCC and grown in DMEM with 10% FBS. We did not authenticate the 
cell line in our laboratory. The CB1 cell line was authenticated as hepatocytes 
by  probing for the markers TSC1 and PTEN that were knocked out only in 
 hepatocytes. CB1 and SNU449 cell lines were tested and found to be free of myco-
plasma contamination.
In vitro phosphatase assay. CB1 cells were lysed in 2× sample buffer (pH 8.8) and 
electrophoresed in two sets using a 10% modified SDS gel (see the ‘Immunoblot 
analysis’ section above). The proteins were transferred onto a nitrocellulose 
 membrane. After transfer, the membrane was cut into two halves. One half of 
the membrane was treated with 0.5 μ g of recombinant LHPP (Abcam, ab116175) 
in 500 μ l Tris-MgCl2 buffer (20 mM Tris-HCl, pH 8.0, and 5 mM MgCl2). The 
other half of the membrane was treated with 1 ml Tris-MgCl2 buffer. The assay 
was carried out at room temperature. After 4 h of treatment with LHPP, the blots 
were washed in casein blocking buffer (pH 8.8) and immunoblotted with 3-pHis 
antibody. The monoclonal antibody used to detect 3-pHis was SC44-1.
INK128 treatment and AAV administration. For acute INK128 administration, 
20-week-old L-dKO (n = 8) and control animals (n = 8) were injected with INK128 
(1 mg kg−1 of body weight) or with the vehicle (intraperitonial injection). INK128 
was dissolved in 5% 1-methyl-2-pyrrolidionone, 15% polyvinylpyrrolidone K30, 
and 80% water. INK128 injection was performed twice (06:00 and 18:00) over 24 h. 
For AAV administration, 8-week-old control and L-dKO mice were infected with 
AAV/DJ-ALBp-RFP (AAV-control) or AAV/DJ-ALBp-RFP-2A-mLhpp (AAV–
LHPP) (5 × 1011 genome copies per mouse) via tail vein injection.
Hepatosphere assays. CB1 cells (2 × 105 cells per well) were seeded in 6-well 
ultra-low attachment plates (Corning, 3471, Costar 6 Well Plate with lid) in 
serum-free DMEM/F12 with recombinant murine epidermal growth factor 
(20 ng ml−1; R&D Systems), murine hepatocyte growth factor (Sigma-Aldrich), 
and 1× B27 serum-free supplement (Invitrogen). Cells were cultured at 37 °C, 
in 5% CO2. On the fifth day, hepatospheres measuring greater than 100 μ m were 
counted for the assay.
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Histopathology and immunohistochemistry. After euthanization of mice, 
the livers were fixed in 4% paraformaldehyde, dehydrated and embedded into 
paraffin wax blocks. Embedded-tissues were cut into 4-μ m-thick sections 
placed on SuperFrost slides (Thermo Scientific) and stained with H&E (Merck). 
Imunohistochemistry was performed using the antibodies NME1 (CST, 3345, dilu-
tion 1:100), NME2 (Abcam, ab60602, 1:100), and LHPP (Novus, NBP1-83273, 
1:200).
HCC tissue specimens and tissue microarrays. Formalin-fixed and paraffin- 
embedded tumour specimens, as well as fresh frozen tissue were obtained from 
the Institute of Pathology, University of Basel, Switzerland. For tissue microarray 
construction, a representative tumour area was selected on an H&E-stained slide 
of the donor block. Afterwards, a core punch with a diameter of 0.6 mm was taken 
from the tumour, and in selected cases from the non-tumoral liver tissue. Core 
punches were transferred to a new paraffin recipient block by using a programmed 
tissue arrayer (Beecher Instruments). The tissue microarray contained 30 HCC 
samples and 30 non-tumour liver control samples. Microarrays were cut in sections 
of 4 μ m thickness and stained with a polyclonal LHPP antibody diluted at 1:200 
using an automatic Benchmark XT staining machine (Ventana Medical Systems 
Inc.). LHPP staining intensity was evaluated by a clinical pathologist (M.S.M,) and 
graded semiquantitatively into: 0 for negative staining, 1 for weak positive  staining, 
2 for moderate positive staining and 3 for strong positive staining (Extended Data 
Fig. 6b). Ten pairs of samples in which one of the tissue sections was washed away 
during staining were ignored during evaluation. While scoring for staining inten-
sity, the pathologist was double blinded to the antigen that was probed and the 
sample identity.
Re-analysis of transcriptomic profiling data. LHPP expression was evaluated 
in 59 HCC needle biopsies, 37 of which were matched with their corresponding 
non-neoplastic liver parenchyma (cirrhotic tissues), using published transcrip-
tomic data (GSE64041)21. CEL files were normalized using the Qlucore Omics 
Explorer software (Qlucore AB). LHPP expression was extracted for each sample. 
RNA sequencing gene expression data including outcomes from 370 hepatocel-
lular carcinomas were retrieved from The Cancer Genome Atlas dataset (TCGA, 
Provisional) using the cbioportal (http://www.cbioportal.org, accessed 4 November 
2016) website. Downregulation of LHPP was defined as z-score ≤ − 1.
LHPP mutation analysis. We interrogated the cBioPortal38,39 and ICGC data 
 portal (https://dcc.icgc.org) for deletions at the LHPP locus in samples across 
33 cancer types. We identified 32 cases harbouring deletion at the LHPP locus. 
Furthermore, we identified 49 mutations across the datasets. We removed duplicate 
TCGA samples that appear in both data portals and variants with > 1% population 
frequencies in the Exome Aggregation Consortium data set, ExAC40. 12 out of 
49 (24.5%) of the mutations are inactivating mutations (Supplementary Table 5).
Serum analysis. Liver damage enzymes ALT, AST and LDH were measured using 
a biochemical analyser (Cobas c 111 analyser, Roche).
Patient material and ethics. All relevant ethical regulations were followed in this 
study. All the experiments with human tissue samples reported in this study were 
approved by the ethics commission of Northwestern Switzerland (EKNZ, approval 
No. 361/12). An informed consent was obtained from the human subjects.
Data availability. All data generated during this study are included in this paper 
and its figures, Extended Data and Supplementary Information. For gel source data, 
see Supplementary Figs 1–13. In addition, publicly available data were analysed in 
this study and are cited wherever relevant.
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Extended Data Figure 1 | Proteomics on L-dKO tumours. a, Liver weight 
(LW) to body weight (BW) ratio (percentage) of 20-week-old L-dKO 
mice (n = 9) and age-matched control mice (n = 9). * * * * P < 0.0001, 
two-sided unpaired t-test. b, mRNA expression analysis in 20-week-old 
L-dKO tumours (n = 3) compared to livers from age-matched control mice 
(n = 3). CD90 (also known as Thy1; * P = 0.0104), CD133 (also known 
as Prom1; * P = 0.0227), Cd44 (* P = 0.0473) and Aldh1 (also known as 
Aldh1a1; * P = 0.0107), two-sided unpaired t-test. Data are mean ± s.d. 
c, Diagram showing the scheme used for mass spectrometry-based 
proteomic analysis. Hepatic proteomes from control mice (n = 6) were 
combined and used as a pooled control against tumours (n = 12) from four 
different L-dKO mice. d, Graph showing number of proteins upregulated 
(red), downregulated (blue) and not regulated (grey) in 12 tumours from c. 
ANOVA-based two-sample t-test with a FDR of 2%, S0 = 1 was used 
to determine regulation (n = 12). e, List of kinases and phosphatases 
(including putative phosphatases) regulated in a minimum of 10 out of 
12 tumours. f, Lhpp mRNA expression analysis in 20-week-old L-dKO 
tumours compared to livers from age-matched control mice (n = 4). 
P = 0.0022, two-sided unpaired t-test. Data are mean ± s.d.
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Extended Data Figure 2 | LHPP protein is conserved in eukaryotes. a, LHPP protein is highly conserved in eukaryotes, from worm to human.  
b, Human LHPP protein shows weak homology to known human histidine phosphatases PHPT1 and PGAM5.
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Extended Data Figure 3 | See next page for caption.
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Extended Data Figure 3 | Loss of LHPP expression is confined to 
L-dKO tumours. a, Quantification of immunoblot (from Fig. 2a) indicates 
reduced LHPP (* * * P = 0.0004) and increased NME1 (* P = 0.0254) and 
NME2 (* P = 0.0105) expression in tumours compared to age-matched 
control littermates (band intensities in each lane are normalized to 
intensity of corresponding calnexin protein levels), control mice (n = 4), 
L-dKO tumours (n = 8). P values are from a two-sided unpaired t-test. 
Data are mean ± s.d. b, Immunoblot analysis of liver tumour (n = 6) 
and non-tumour (n = 3) tissue from three independent 20-week-old 
L-dKO mice shows tumour-specific loss of LHPP expression. Ponceau S 
image of the whole blot is also included. For full scan, see Supplementary 
Fig. 3. c, Immunohistochemistry analyses showing increased NME1 
expression in L-dKO liver compared to liver from control mice. Although 
L-dKO tumours displayed reduced expression of LHPP, hepatic LHPP 
expression in the non-tumour region was comparable to control mice. 
Parallel tissue sections that were processed similarly (without primary 
antibody) served as antibody control. Similar results were obtained in 
livers from 4 independent control mice and L-dKO mice. d, Immunoblot 
analysis of liver from control mice and L-dKO liver tumours treated with 
INK128 (1 mg kg−1 body weight; two intraperitonial injections in 24 h; 
n = 4 mice per condition, lysates from two mice are pooled into one lane). 
LHPP expression remains unchanged, but NME1 and NME2 expression 
is reduced considerably in L-dKO mice after INK128 treatment. For full 
scans, see Supplementary Fig. 4.
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Extended Data Figure 4 | See next page for caption.
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Extended Data Figure 4 | LHPP is a protein histidine phosphatase.  
a, Diagram of NME1 and NME2 autophosphorylation on His118. The 
high-energy phosphate is later transferred from the histidine kinase 
dimer pair to the histidine on the substrate. b, CB1 cell lysate was 
electrophoresed and transferred onto a nitrocellulose membrane. Two sets 
of the membrane were treated with recombinant full-length LHPP (for 
4 h) in TMD buffer (see Methods) and the other set of the membrane was 
treated with plain TMD buffer (pH 8.5). Immunoblotting analysis of both 
the membranes with 3-pHis antibody (clone SC44-1) indicates that LHPP 
is a protein pHis phosphatase. For full scans, see Supplementary Fig. 6.  
c, Immunoblotting shows no apparent change pSer/Thr or  
pTyr levels in CB1 cells infected with adenovirus containing LHPP 
compared to cells infected with RFP-only control. Similar result 
was observed in two independent experiments. For full scans, see 
Supplementary Fig. 9. d, e, Immunoblotting (d) and quantification (e)  
show a reduction in 3-pHis levels in SNU449 cells infected with 
adenovirus containing LHPP compared to control-infected cells. Similar 
results were observed in four independent biological experiments.  
For full scans, see Supplementary Fig. 8. A 50–60% confluent dish was first 
infected, 24 h after infection, the cells were trypsinized and 2 × 105 cells 
were seeded into a 6-well adherent tissue culture dish and 24 h later lysed 
in pHis compatible buffer (see Methods). The monoclonal antibodies used 
to detect 3-pHis and 1-pHis were SC44-1 and SC1-1, respectively (n = 4).  
* * P = 0.0019, two-sided ratio paired t-test. Data are mean ± s.d. f, Colony-
forming assay in CB1 cells (n = 3 biologically independent experiments) 
and SNU449 (n = 5 biologically independent experiments) cells shows 
reduced proliferation upon LHPP over expression. Twelve hours after 
infection, CB1 (2 × 104 per well) and SNU449 (4 ×  104 per well) cells  
were seeded into a 6-well plate tissue culture plate and stained with  
crystal violet (2% crystal violet in 20% methanol) on day 7. * * P = 0.0026, 
* * * * P < 0.0001, two-sided unpaired t-test. Data are mean ± s.d. See 
Methods for further details. g, Photomicrographs of LHPP-overexpressing 
CB1 cells (left) displayed reduced ability to form hepatospheres in ultralow 
attachment plates; n = 3 biologically independent experiments.  
* * P = 0.0024, two-sided unpaired t-test. Data are mean ± s.d.  
(see Methods).
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Extended Data Figure 5 | See next page for caption.
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Extended Data Figure 5 | LHPP is a tumour suppressor. a, Left 
and middle, colony-forming assay in SNU449 cells shows increased 
proliferation upon LHPP knockdown using pooled short interfering RNA 
(siRNA). Then 36 h after infection, SNU449 cells were re-transfected with 
LHPP siRNA and 4 × 104 cells per well were seeded into a 6-well tissue 
culture plate and allowed to proliferate for another 3 days. At the end of 
the third day, cells were stained with crystal violet (2% crystal violet in 
20% methanol), and similar results were obtained from five biologically 
independent experiments. * * P = 0.0075, two-sided unpaired t-test. Data 
are mean ± s.d. Right, immunoblot analysis (n = 1) revealed a reduction 
in LHPP protein levels after siRNA transfection. Longer exposure of 
the LHPP blot relative to the blot in Extended Data Fig. 4d. In addition 
to immunobloting, a reduction in LHPP transcript levels after siRNA 
transfection was also confirmed in two independent experiments (data  
not shown). For full scans, see Supplementary Fig. 10. b, Immunoblot 
analysis (bottom) and quantification (top) of non-tumour and tumour 
liver lysates confirmed LHPP overexpression in 20-week-old AAV-LHPP-
infected mice (as in Fig. 3e). For full scans, see Supplementary Fig. 11.  
c, Serum extracted from mice in (Fig. 3e) and analysed for ALT, AST and 
LDH levels shows a reduction in liver damage upon AAV-LHPP infection, 
unit per litre (U l−1) (control mice infected with AAV-control and AAV-
LHPP virus (n = 4), L-dKO mice infected with AAV-control (n = 5) and 
AAV-LHPP virus (n = 8)). Data are mean ± s.d. P values are by one-way 
ANOVA with Tukey’s multiple-comparison test. ALT (adjusted  
* * * P = 0.004, * * * * P < 0.0001), AST (adjusted * * P = 0.013 for control 
mice versus L-dKO mice transfected with AAV-control; adjusted  
* * P = 0.0075 for L-dKO mice transfected with AAV-control versus  
L-dKO mice transfected with AAV-LHPP), LDH (adjusted * P = 0.0196,  
* * P = 0.0037).
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Extended Data Figure 6 | See next page for caption.
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Extended Data Figure 6 | LHPP is a tumour suppressor in human HCC. 
a, Representative immunohistochemistry images from the LHPP-stained 
tissue microarray. Scale bar, 100 μ m. b, Representative images and staining 
intensities of LHPP staining in the tissue microarray. c, Tissue microarray 
(TMA) indicates that LHPP is significantly downregulated in human  
HCC compared to adjacent non-tumour tissue (n = 20 HCC patients,  
* * * * P < 0.0001, two-sided paired t-test). d, Box plots showing a 
significant reduction in LHPP expression in HCC tissue compared to 
adjacent non-tumour tissue (n = 59). * * * * P < 0.0001, two-sided Mann–
Whitney U test. Non-tumour (minimum, − 1.422, median, 0.03329, 
maximum, 0.6179, lower 95% confidence interval (CI) of mean − 0.0931, 
upper 95% CI of mean 0.0931) and HCC (minimum, − 1.797, median, 
− 0.3729, maximum, 0.7683, lower 95% CI of mean − 0.5328, upper 95% 
CI of mean − 0.2506). Expression of PHPT1 and PGAM5 was not reduced 
in HCC. e, Box plots showing a strong reduction in LHPP expression in 
Edmondson grade III/IV tumours (aggressive tumours, n = 17) compared 
to Edmondson grade I/II tumours (less aggressive tumours, n = 42).  
* * P = 0.0036, two-sided Mann–Whitney U test. Edmondson grade I/II 
(minimum, − 1.592, median, − 0.2594, maximum 0.7683, lower 95% CI of 
mean − 0.3987, upper 95% CI of mean − 0.0986) and III/IV (minimum, 
− 1.797, median, − 0.5281, maximum, − 0.09671, lower 95% CI of mean 
− 1.018, upper 95% CI of mean − 0.4717). f, Lollipop plot showing the 
distribution of mutations in LHPP across pan-cancer datasets in the 
TCGA and ICGC portal. Solid white circles indicate missense mutations, 
red circles indicate inactivating mutations (including nonsense mutations, 
splice site mutations and frameshift deletions; detailed list of mutations is 
provided in Supplementary Table 5).
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`    Experimental design
1. Sample size
Describe how sample size was determined. For animal experiments, complying with animal ethical guidelines, a minimal number of 
animals that could give a statistically significant result were used.  After genotyping, age and 
sex matched mice were chosen for the study. Littermate Cre negative mice served as 
controls. 
All the human samples we could obtain from the hospital were used for experimentation  
(n=7 for western blotting and n=20 for tissue microarray). 
Further details can be found in the figure legends 1 – 4; page number 11 – 14. 
2. Data exclusions
Describe any data exclusions. No data were excluded for the analysis
3. Replication
Describe the measures taken to verify the reproducibility
of the experimental findings.
All attempts at replication were successful.
4. Randomization
Describe how samples/organisms/participants were
allocated into experimental groups.
Littermate controls were used for different treatments in all animal experiments. No other 
randomization protocol was applied beyond this criterion.
5. Blinding
Describe whether the investigators were blinded to
group allocation during data collection and/or analysis.
Figure 3: The pathologist was blind to the treatments performed. 
Figure 4: While scoring for staining intensity, the pathologist was double blind to 1. the 
antigen that was probed, and 2. the sample identity 
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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6. Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the
Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present 
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
`   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this
study.
Proteome discoverer version 1.4 (analysis of proteome); Progenesis QI (alignment of 
proteome); Perseus version 1.4.0.2 (statistical analysis of proteome); MaxQuant, 
version 1.5.3.8 (analysis of proteome); FileMaker Pro version12 databank (in-house 
generated databank); ImageJ software version 2.0.0 (quantify the immunoblots); 
Tecan i-control version 1.11.1.0 (quantify crystal violet staining); Qlucore Omics 
Explorer version 3.2 (transcriptome profiling); GraphPad Prism version 7.0 (plotting 
graphs and statistical analysis)
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
`   Materials and reagents
Policy information about availability of materials
8. Materials availability
Indicate whether there are restrictions on availability of
unique materials or if these materials are only available
for distribution by a third party.
All unique materials used in this study are readily available from the authors
9. Antibodies
Describe the antibodies used and how they were validated
for use in the system under study (i.e. assay and species).
Antibodies obtained from our collaborator;
Phospho histidine antibodies (both 1-pHis and 3-pHis antibodies) are already published (Fuhs, S. R. et al. Monoclonal 1- and 3-
phosphohistidine antibodies: new tools to study histidine phosphorylation. Cell 162, 198–210, 400 (2015) and are obtained from our 
collaborator Prof. Tony Hunter at Salk Institute for Biological Sciences.
Below mentioned antibodies are available commercially;
PTEN (CST (Cell Signaling Technology), 9188), TSC1 (Bethyl, A300-316A), phospho-S6 (CST, 4856), total S6 (CST, 2217), pAKT 
S473 (CST, 9271), total Akt (CST, 9272), Calnexin (Enzo, ADI-SPA-860), NME1 (CST, 3345), NME2 (Abcam, ab60602), and 
LHPP (Novus, NBP1-83273). HRP-coupled anti-mouse (115-035-774) and anti-rabbit (211-032-171) secondary antibodies were 
purchased from Jackson laboratories.
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10. Eukaryotic cell lines
a. State the source of each eukaryotic cell line used. CB1 is an in-house derived cell line; 
SNU449 are from ATCC 
b. Describe the method of cell line authentication used.
c. Report whether the cell lines were tested for
mycoplasma contamination.
SNU449 cell line has not been authenticated.
CB1 cells are generated in-house. CB1 cell line is authenticated as hepatocytes by probing for the markers 
TSC1 and PTEN, that were knocked out only in hepatocytes. Western blot data is available if necessary.
d. If any of the cell lines used are listed in the database
of commonly misidentified cell lines maintained by
ICLAC, provide a scientific rationale for their use.
The cell lines used in this paper are not under misidentified cell lines maintained by ICLAC.
`    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide all relevant details on animals and/or
animal-derived materials used in the study.
Mice used were on the mixed genetic background (C57BL/6J, 129/SvJae, BALB/cJ). All experiments were 
conducted on 20 week old male mice, unless mentioned. In figure 2B, animals belonging to ages 6 weeks, 12 
weeks, 16 weeks and 20 weeks were used. In figure 3E, AAV injection was performed in 8 week old mice and the 
experiment was terminated at 20 weeks.
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population
characteristics of the human research participants.
All the experiments with human tissue samples reported in this study were approved by the ethics commission of 
Northwestern Switzerland (EKNZ, approval No. 361/12). Patient details: 4/7 tumors were poorly differentiated liver 
tumors and 3/7 were moderately differentiated liver tumors. Age of the patients at the time of biopsy collection 
was between 61-85 years.
The cell lines used in this study are mycoplasma negative
